Hepatitis C
Antiviral treatment improves outcomes in patients with advanced cirrhosis
Hepatitis C drug shown to reduce the need for transplant and lower mortality rate in patients with advanced liver disease.
The effect of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection has not been well established in patients with decompensated cirrhosis, an advanced form of the disease that usually requires transplantation or it can be fatal.
In a study presented at the Joint International Congress of ILTS, ELITA & LICAGE in Prague, Czech Republic[1] (26 May 2017), researchers compared 623 people who received sofosbuvir in randomised trials with 1,857 untreated controls from a liver transplant waiting list.
At 48 weeks, 95% of patients in the sofosbuvir group were alive and had not undergone transplant compared with 30% of controls. The liver transplant rate was only 3% in sofosbuvir patients compared with 43% among controls.
HCV treatment should be considered for patients with decompensated cirrhosis, the researchers conclude.
Citation: Clinical Pharmacist DOI: 10.1211/CP.2017.20203089
Recommended from Pharmaceutical Press
- Previous
- Next
Drugs of Abuse
A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.
£38.00Buy now
Sport and Exercise Medicine for Pharmacists
All the information you need to provide patients with evidence-based advice on sports and exercise related health matters.
£27.00Buy now.jpg)
Adverse Drug Reactions
A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.
£38.00Buy now
English Delftware Drug Jars
This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.
£54.00Buy now
Complete Guide to Medical Writing (The)
Effectively communicate scientific and medical information with The Complete Guide to Medical Writing.
£27.00Buy now
Print 
PDF
Have your say
For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.